RinLaures LLC specializing in biopharma IP
Helping clients achieve their business goals by protecting innovations from concept to commercial product
Li-Hsien (Lily) Rin-Laures, MD
Bio
Dr. Rin-Laures draws on three decades of experience to help biopharma clients achieve their intellectual property and business goals. She has managed patent portfolios for nine FDA-approved drugs and provided strategic counseling to a variety of clients from start-ups to Fortune 500 companies. She advises clients on complex intellectual property issues, including PTAB proceedings, oppositions, and patent strategy relating to new pharmaceutical/biotechnology product development, as well as the interface with FDA regulations and related exclusivity provisions. She has extensive experience in negotiating licenses and strategic alliances, and has presented to the Board of Directors of a number of privately and publicly held companies.
Education
- J.D., cum laude, Harvard Law School, 1992
- M.D., Northwestern Medical School, 1988
- B.A., chemistry, with honors, Johns Hopkins University, 1984
LMG Life Sciences Hall of Fame and 2014 "Patent Prosecution Pharmaceutical Attorney of the Year"
Other awards and recognition:
- Awarded "Patent Strategy & Management Attorney of the Year - Midwest", LMG Life Sciences, 2020, 2019 & 2016 (shortlisted in 2023, 2018, 2017)
- RinLaures LLC shortlisted as one of four finalists for "Intellectual Property Firm to Watch", LMG Life Sciences, 2017
- Recognized as a National Law Journal's (NLJ) "Outstanding Women Lawyers", 2015
- Leading Law Firm Rainmaker in MCCA's Diversity & The Bar, 2012
- Identified as one of "Women Worth Watching", 2014
- Life Sciences Star as ranked by LMG Life Sciences, 2012-2020, 2023
- IP Star as ranked in Managing IP’s IP Stars Survey 2013-2023
- Top 250 Women in IP ranked by Managing IP, 2014 and 2016-2023
- World's Leading IP Strategist (IAM 300), 2018-2020 and World’s Leading Patent Professionals (IAM 1000) ranked by Intellectual Asset Management (IAM) magazine, 2013-2020, 2023-24
- Inducted into Law Bulletin Publishing Company’s "40 Illinois Attorneys Under Forty To Watch" Hall of Fame in 2014
- Voted an "Illinois Super Lawyer" for a number of years
Professional Organization Involvement
- Board of Directors, Women In Bio national organization 2016-2019
- Board of Directors, PTAB Bar Association, 2019-2022; Secretary 2022-2023; Vice President 2023-2024
- President-elect, PTAB Bar Association, 2024-2025
Client Testimonials
"Lily has been instrumental in helping BioMarin to establish patent portfolios for many of BioMarin’s biologic and small molecule programs. Because of her deep scientific knowledge and extensive legal experience, Lily has been successful in obtaining issuance of patents that provide value in extending and supporting market exclusivity of many Company products. . . . Because of her combined corporate and patent legal background and experience as an Executive In-house Counsel, Lily has the ability to provide a global perspective that incorporates patent strategy with business objectives and corporate goals."
Luisa Bigornia, Ph.D., Vice President of Intellectual Property, BioMarin Pharmaceutical Inc.
"Lily has been a unique partner and colleague in helping our company build its strong patent estate. She is sharp, thoughtful, creative and very effective. We would not be where we are if it wasn’t for Lily and her team."
Carlos Paya, former CEO, Immune Design Corporation
"Lily consistently provides creative counselling tempered with integrity and practicality to achieve optimum outcomes for her clients. A natural communicator, she is responsive, good humoured and able to convey complex strategic and tactical thinking and advice in a manner that makes decision making simple for the client. A first-rate attorney . . . I wouldn't exchange her for anyone."
Phillip Ansell, retired Associate General Patent Counsel at a Forbes Global 2000 company
Representative work
Prosecuted patents relating to Amgen's ENBREL product, including successfully arguing an appeal within the patent office.
Advise CRISPR Therapeutics on intellectual property in the CRISPR-Cas9 field since its formation. Represent involved party as co-lead counsel in Interference Nos. 106,115, 106,127 and 106,132 relating to CRISPR-Cas9 technology.